Orthostatic hypotension (also called postural hypotension) is a sudden dip in blood pressure that happens when you stand up after you’ve been sitting or lying down. Sometimes, it may take a ...

Orthostatic hypotension increases in prevalence with age; aging is associated with reduced baroreflex responsiveness, decreased cardiac compliance, and attenuation of the vestibulosympathetic reflex.

Orthostatic hypotension is a cardinal feature of multiple-system atrophy. The upright posture provokes syncopal episodes that prevent patients from standing and walking for more than brief periods.

Orthostatic hypotension is a common form of low blood pressure that occurs when you suddenly get up from a seated or lying position. Here’s what you can do to bring your blood pressure levels ...

Postural hypotension, also called orthostatic hypotension, is a sudden and exaggerated reduction in blood pressure that happens in some people when they stand up. Symptoms can include light ...

Possible mechanisms underlying orthostatic hypotension in SCI, such as changes in sympathetic activity, altered baroreflex function, the lack of skeletal muscle pumping activity, ...

Orthostatic hypotension can be severe in people with certain forms of the disease. Orthostatic hypotension can be caused by the disease itself or by the medications used to treat Parkinson's disease .

Orthostatic hypotension occurs when inadequate blood gets to the brain because of a change in position. Normally, sitting or standing will signal the blood vessels in the legs and lower body to ...

Citation: Lowry M et al (2024) Orthostatic hypotension 1: the physiology of blood pressure regulation. Nursing Times [online]; 120: 11. This article is the updated version of Lowry M et al (2016) ...

Did you know that certain medications can cause symptom of 'Symptomatic Orthostatic Hypotension'. Find these drugs listed on the page and be warned of similar symptoms as possible side-effects.

Clinical-stage biopharmaceutical company CuraSen Therapeutics has treated the first subject in the Phase I trial of CuraAX to ...